This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moskalenko, M.
Right arrow Articles by Patel, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moskalenko, M.
Right arrow Articles by Patel, S. D.

 Previous Article  |  Next Article 

Journal of Virology, February 2000, p. 1761-1766, Vol. 74, No. 4
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure

Marina Moskalenko, Lili Chen, Melinda van Roey, Brian A. Donahue, Richard O. Snyder, James G. McArthur, and Salil D. Patel*

Department of Preclinical Biology and Immunology, Cell Genesys Inc., Foster City, California 94404

Received 23 July 1999/Accepted 10 November 1999

Recombinant adeno-associated virus type 2 (AAV) is a common vector used in human gene therapy protocols. We characterized the humoral immune response to AAV and observed that 80% of normal human subjects have anti-AAV antibodies and that 18% have neutralizing antibodies. To analyze the effect of neutralizing antibodies on AAV readministration, we attempted to deliver recombinant AAV expressing human factor IX (AAV-hFIX) intraportally into the livers of mice which had been preexposed to AAV and shown to harbor a neutralizing antibody response. While all naive control mice expressed hFIX following administration of AAV-hFIX, none of the mice with preexisting immunity expressed hFIX, even after transient immunosuppression at the time of the second administration with anti-CD4 or anti-CD40L antibodies. This suggests that preexisting immunity to AAV, as measured by a neutralizing antibody response, may limit AAV-mediated gene delivery. Using human sera in an enzyme-linked immunosorbent assay for AAV and a capsid peptide scan library to block antibody binding, we mapped seven regions of the AAV capsid containing immunogenic epitopes. Using pools of these peptides to inhibit the binding of neutralizing antibodies, we have identified a subset of six peptides which potentially reconstitute a single neutralizing epitope. This information may allow the design of reverse genetic approaches to circumvent the preexisting immunity that can be encountered in some individuals.

* Corresponding author. Mailing address: Cell Genesys Inc., Department of Preclinical Biology and Immunology, 324 Lakeside Dr., Foster City, CA 94404. Phone: (650) 425-4420. Fax: (650) 358-0645. E-mail: spatel{at}cellgenesys.com.

Journal of Virology, February 2000, p. 1761-1766, Vol. 74, No. 4
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ito, T., Yamamoto, S., Hayashi, T., Kodera, M., Mizukami, H., Ozawa, K., Muramatsu, S.-i. (2009). A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies. Ann Clin Biochem 46: 508-510 [Abstract] [Full Text]  
  • Johnson, J. S., Samulski, R. J. (2009). Enhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus. J. Virol. 83: 2632-2644 [Abstract] [Full Text]  
  • Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., Muruve, D. A. (2008). Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors. J. Virol. 82: 2727-2740 [Abstract] [Full Text]  
  • Li, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., Samulski, R. J. (2007). Adeno-Associated Virus Type 2 (AAV2) Capsid-Specific Cytotoxic T Lymphocytes Eliminate Only Vector-Transduced Cells Coexpressing the AAV2 Capsid In Vivo. J. Virol. 81: 7540-7547 [Abstract] [Full Text]  
  • Murray, S., Nilsson, C. L., Hare, J. T., Emmett, M. R., Korostelev, A., Ongley, H., Marshall, A. G., Chapman, M. S. (2006). Characterization of the Capsid Protein Glycosylation of Adeno-Associated Virus Type 2 by High-Resolution Mass Spectrometry.. J. Virol. 80: 6171-6176 [Abstract] [Full Text]  
  • Adriaansen, J., Vervoordeldonk, M. J. B. M., Tak, P. P. (2006). Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45: 656-668 [Abstract] [Full Text]  
  • Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., Kleinschmidt, J. A. (2006). Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1. J. Virol. 80: 2621-2630 [Abstract] [Full Text]  
  • Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., Pierce, G. F. (2006). Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107: 1810-1817 [Abstract] [Full Text]  
  • Lochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., Colosi, P. (2006). Mutations on the External Surfaces of Adeno-Associated Virus Type 2 Capsids That Affect Transduction and Neutralization. J. Virol. 80: 821-834 [Abstract] [Full Text]  
  • Adriaansen, J, Tas, S W, Klarenbeek, P L, Bakker, A C, Apparailly, F, Firestein, G S, Jorgensen, C, Vervoordeldonk, M J B M, Tak, P P (2005). Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis 64: 1677-1684 [Abstract] [Full Text]  
  • Peden, C. S., Burger, C., Muzyczka, N., Mandel, R. J. (2004). Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain. J. Virol. 78: 6344-6359 [Abstract] [Full Text]  
  • Opie, S. R., Warrington, K. H. Jr., Agbandje-McKenna, M., Zolotukhin, S., Muzyczka, N. (2003). Identification of Amino Acid Residues in the Capsid Proteins of Adeno-Associated Virus Type 2 That Contribute to Heparan Sulfate Proteoglycan Binding. J. Virol. 77: 6995-7006 [Abstract] [Full Text]  
  • Bowles, D. E., Rabinowitz, J. E., Samulski, R. J. (2002). Marker Rescue of Adeno-Associated Virus (AAV) Capsid Mutants: a Novel Approach for Chimeric AAV Production. J. Virol. 77: 423-432 [Abstract] [Full Text]  
  • Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., Chapman, M. S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99: 10405-10410 [Abstract] [Full Text]  
  • Mastakov, M. Y., Baer, K., Symes, C. W., Leichtlein, C. B., Kotin, R. M., During, M. J. (2002). Immunological Aspects of Recombinant Adeno-Associated Virus Delivery to the Mammalian Brain. J. Virol. 76: 8446-8454 [Abstract] [Full Text]  
  • Ried, M. U., Girod, A., Leike, K., Buning, H., Hallek, M. (2002). Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors. J. Virol. 76: 4559-4566 [Abstract] [Full Text]  
  • Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., Kleinschmidt, J. A. (2000). Monoclonal Antibodies against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection. J. Virol. 74: 9281-9293 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»